menu
    • menu

    Company profile for Alzheon

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alzheon’s ALZ-801 is currently the only oral disease-modifying treatment in late-stage testing for Alzheimer’s disease. We believe that ALZ-801 has the potential to significantly slow or stop disease progression and even prevent the onset of symptoms. Development of ALZ-801, a well tolerated new treatment, is based on seven years of Alzheon research into the biology of AD and data from 2000 patients treated with its act...
    Alzheon’s ALZ-801 is currently the only oral disease-modifying treatment in late-stage testing for Alzheimer’s disease. We believe that ALZ-801 has the potential to significantly slow or stop disease progression and even prevent the onset of symptoms. Development of ALZ-801, a well tolerated new treatment, is based on seven years of Alzheon research into the biology of AD and data from 2000 patients treated with its active ingredient tramiprosate.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlzheonUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    111 Speen Street Suite 306 Framingham, MA 01701
    Telephone
    Telephone
    1-508-861-7709
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alzheon.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzheon Doses First Subject in ALZ-507 Phase 1 Trial
    Alzheon Doses First Subject in ALZ-507 Phase 1 Trial

    07 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-07/alzheon-advances-industry-leading-portfolio-of-oral-anti-amyloid-aggregation-inhibitors-with-first-s

    PHARMIWEB
    07 Apr 2026
    Share Share
    Alzheon To Present Clinical, Imaging, And Fluid Biomarker
    Alzheon To Present Clinical, Imaging, And Fluid Biomarker

    10 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260310939743/en/Alzheon-to-Present-Clinical-Imaging-and-Fluid-Biomarker-Results-from-Trials-with-Oral-ValiltramiprosateALZ-801-at-2026-ADPD-Conference-in-Copenhagen-Denmark

    BUSSINESSWIRE
    10 Mar 2026
    Share Share
    Alzheon Validate Valiltramiprosate Mechanism In Alzheimer Disease
    Alzheon Validate Valiltramiprosate Mechanism In Alzheimer Disease

    03 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260203941149/en/Alzheon-Reports-Plasma-Biomarker-Results-from-Phase-3-and-2-Studies-of-ValiltramiprosateALZ-801-Validating-Its-First-in-Class-Mechanism-of-Action-and-Underscoring-Benefits-in-Cognition-Function-and-Brain-Volume-Protection-in-Alzheimers-Patients

    BUSINESSWIRE
    03 Feb 2026
    Share Share
    Alzheon Reports Evidence Supporting Hippocampal Volume Marker
    Alzheon Reports Evidence Supporting Hippocampal Volume Marker

    02 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251202859047/en/Alzheon-Announces-Peer-Reviewed-Publication-Providing-Evidence-for-Hippocampal-Volume-as-Surrogate-Marker-for-Clinical-Benefit-and-Neurodegeneration-in-Early-Alzheimers-Disease

    BUSINESSWIRE
    02 Dec 2025
    Share Share
    Alzheon To Unveil Oral Valiltramiprosate Results At CTAD
    Alzheon To Unveil Oral Valiltramiprosate Results At CTAD

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125136522/en/Alzheon-to-Present-Multiple-Clinical-Neuroimaging-and-Modeling-Results-for-Oral-ValiltramiprosateALZ-801-from-Phase-2-and-3-Studies-at-CTAD-Conference-in-San-Diego-December-14-2025

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    Alzheon Publishes APOLLOE4 Ph3 Data on Oral ALZ-801 in Early AD
    Alzheon Publishes APOLLOE4 Ph3 Data on Oral ALZ-801 in Early AD

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014241744/en/Alzheon-Announces-Peer-Reviewed-Scientific-Publication-of-Results-from-Pivotal-APOLLOE4-Phase-3-Trial-of-Oral-ValiltramiprosateALZ-801-in-APOE44-Homozygous-Individuals-with-Early-Alzheimers-Disease

    BUSINESSWIRE
    14 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search